New study to see how well elranatamab works in everyday care for myeloma patients
NCT ID NCT07391761
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand the drug's real-world effectiveness and treatment patterns outside of a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab
What this could lead to
If successful, this study could confirm that elranatamab is effective outside of clinical trials, helping doctors in Taiwan make better treatment decisions for multiple myeloma.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. It is small (30 patients) and only in Taiwan, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaohsiung Chang Gung Memorial Hospital
Kachsiung, 833, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan